ATG-107

ATG-107 is a bispecific T-cell engager (TCE) developed by Antengene. It utilizes a novel "2+1" format to simultaneously target FLT3 (Fms-like tyrosine kinase 3), which is overexpressed in the majority of acute myeloid leukemia (AML) cases, and CD3 on T cells. The molecule binds bivalently to FLT3, concealing the CD3 binding site until FLT3 engagement occurs, thereby redirecting T cells to attack AML cells with high specificity and minimizing off-target activation. Preclinical studies have demonstrated potent FLT3-dependent T-cell activation and cytotoxicity against AML cells regardless of their FLT3 mutation status, as well as strong anti-leukemic efficacy in humanized mouse models. The AnTenGager™ platform underlying ATG-107 aims to reduce systemic CD3 activation and cytokine release syndrome risk compared to conventional approaches[1][4][5][6].